Top 10 Podcasts of 2019 from the BioHealth Capital Region

Published on :

Top 10 Podcasts of 2019 from the BioHealth Capital Region Check out these Podcasts Featuring Some of the Top Biohealth Industry Leaders and Executives from the Region To say it has been an exciting year in the BioHealth Capital Region (BHCR) is an understatement. Whether it was Viela Bio’s IPO, Kite Pharma’s announcement that it [….]

First Car-T for an Autoimmune Disease Enters Clinic

Published on :

First Car-T for an Autoimmune Disease Enters Clinic Maryland-Based Cartesian Therapeutics Initiates CAR-T Clinical Trial in Myasthenia Gravis Gaithersburg, MD, November 5, 2019 – see full press release Founded in 2016 by a pair of MD/PhD scientists and serial life sciences entrepreneurs, Cartesian Therapeutics is out to rapidly translate discoveries into clinical trials, and trials into [….]

Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome

Published on :

Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome October 31, 2019 07:30 ET | Source: NexImmune, Inc. IND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplant IND clearance validates Company’s Artificial Immune Modulation [….]

Intralytix Opens New HQ in Columbia, Maryland for Phage Research and Manufacturing Facility

Published on :

From left to right:

– Per Falk, President & CSO, Ferring Pharmaceuticals
– John Woloszyn, Founder, President & CEO, Intralytix, Inc.
– Calvin Ball, County Executive, Howard County, Maryland
– Alexander Sulakvelidze, Founder, EVP & CSO, Intralytix, Inc.
– Antoine Baule, CEO, Lesaffre Compagnie

Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors

Published on :

Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors October 04, 2019Original Press Release GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately $7 [….]